Loading
A phase 1/2 trial of U16 in non-Hodgkin lymphoma, run by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, now recruiting.
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05768529 by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, with 100 participants planned, started 2023-03-28 and due to reach its primary completion in 2024-12-31. Interventions recorded: U16.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Unicar-Therapy and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/